



## **Written Testimony in Support of SB 477 and SB 478**

January 21, 2026

Dear Members of the New Hampshire Senate Health and Human Services Committee,

On behalf of Patients Rising, a national patient advocacy organization dedicated to empowering patients and caregivers with the information, transparency, and tools they need to navigate the healthcare system, we respectfully submit this written testimony in support of **SB 477** and **SB 478**.

Patients Rising works with patients and families across the country who are struggling not because care does not exist—but because the system meant to serve them is opaque, fragmented, and often misaligned with patient needs. These two bills represent thoughtful, patient-centered steps toward restoring trust and accountability in that system.

### **Support for SB 477 – Increasing Transparency in the 340B Drug Pricing Program**

The 340B Drug Pricing Program was created to help safety-net providers stretch scarce resources and better serve vulnerable patients. However, the lack of consistent public reporting has made it increasingly difficult for patients, policymakers, and regulators to understand whether those savings are reaching the people the program was designed to help.

SB 477 does not alter federal pricing or interfere with confidential negotiations. Instead, it establishes reasonable, uniform reporting requirements that will allow New Hampshire to better understand:

- How many patients are actually benefiting from 340B-discounted drugs,
- How revenues from those drugs are generated, and
- Whether savings are being used in ways that meaningfully improve patient access and affordability.

Transparency is not punitive—it is foundational. Patients deserve to know whether programs created in their name are working as intended. SB 477 moves New Hampshire closer to that goal while respecting the boundaries of the federal program.

## **Support for SB 478 – Strengthening Prescription Drug Affordability and PBM Accountability**

Patients consistently tell us that prescription drug costs feel unpredictable and unfair, even when they are insured. One of the most common sources of confusion and frustration is the role of pharmacy benefit managers (PBMs), whose financial incentives are often hidden from both patients and plan sponsors.

SB 478 takes important steps to realign incentives across the drug supply chain by:

- Eliminating spread pricing practices that inflate costs without adding patient value,
- Requiring rebates and discounts to flow back to plans and consumers,
- Delinking PBM compensation from drug list prices, and
- Strengthening oversight and auditability to ensure fair pharmacy reimbursement practices.

These reforms are not about choosing winners or losers in the marketplace. They are about ensuring that entities paid to manage benefits are rewarded for lowering costs and improving access—not for exploiting price differentials that patients never see.


### **Conclusion**

Taken together, SB 477 and SB 478 advance a shared principle: patients should not be the last to know how their healthcare dollars are being used. Transparency and accountability are essential to affordability, trust, and long-term system sustainability.

Patients Rising respectfully urges the Committee to support both bills and to continue New Hampshire's leadership in patient-focused healthcare reform.

Thank you for your consideration and for your service to the people of New Hampshire.

Sincerely,



**Terry Wilcox**

Co-Founder & Chief Mission Officer

Patients Rising

[www.patientsrising.org](http://www.patientsrising.org)